{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T17:50:34Z","timestamp":1790531434801,"version":"4.1.0"},"posted":{"date-parts":[[2022,8,24]]},"group-title":"Genomics","reference-count":54,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,4,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Viruses and virally-derived particles have the intrinsic capacity to deliver molecules to cells, but the difficulty of readily altering cell-type selectivity has hindered their use for therapeutic delivery. Here we show that cell surface marker recognition by antibody fragments displayed on membrane-derived particles encapsulating CRISPR-Cas9 protein and guide RNA can target genome editing tools to specific cells. These Cas9-packaging enveloped delivery vehicles (Cas9-EDVs), programmed with different displayed antibody fragments, confer genome editing in target cells over bystander cells in mixed cell populations both\n                  <jats:italic>ex vivo<\/jats:italic>\n                  and\n                  <jats:italic>in vivo<\/jats:italic>\n                  .\n                <\/jats:p>\n                <jats:p>This strategy enabled the generation of genome-edited chimeric antigen receptor (CAR) T cells in humanized mice, establishing a new programmable delivery modality with widespread therapeutic utility.<\/jats:p>\n                <jats:sec>\n                  <jats:title>One-Sentence Summary<\/jats:title>\n                  <jats:p>\n                    Cell-specific molecular delivery with enveloped delivery vehicles (EDVs) enables genome editing\n                    <jats:italic>ex vivo<\/jats:italic>\n                    and\n                    <jats:italic>in vivo<\/jats:italic>\n                    .\n                  <\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2022.08.24.505004","type":"posted-content","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T23:55:20Z","timestamp":1661385320000},"source":"Crossref","is-referenced-by-count":7,"title":["Programmable enveloped delivery vehicles for human genome engineering\n                  <i>in vivo<\/i>"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7136-1757","authenticated-orcid":false,"given":"Jennifer R.","family":"Hamilton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1102-6997","authenticated-orcid":false,"given":"Evelyn","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara S.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy R.","family":"Sandoval Espinoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Hyung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marena","family":"Trinidad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9161-999X","authenticated-orcid":false,"given":"Jennifer A.","family":"Doudna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2023040502200521000_2022.08.24.505004v2.1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1021\/acschembio.7b00680","article-title":"The Promise and Challenge of In Vivo Delivery for Genome Therapeutics","volume":"13","year":"2018","journal-title":"ACS Chem. Biol"},{"key":"2023040502200521000_2022.08.24.505004v2.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0565-5"},{"key":"2023040502200521000_2022.08.24.505004v2.3","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","article-title":"Therapeutic in vivo delivery of gene editing agents","volume":"185","year":"2022","journal-title":"Cell"},{"key":"2023040502200521000_2022.08.24.505004v2.4","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba7365"},{"key":"2023040502200521000_2022.08.24.505004v2.5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 Gene Editing for Sickle Cell Disease and \u03b2-Thalassemia","volume":"384","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"2023040502200521000_2022.08.24.505004v2.6","doi-asserted-by":"publisher","DOI":"10.1126\/science.abg6155"},{"key":"2023040502200521000_2022.08.24.505004v2.7","unstructured":"Editas Medicine Announces Positive Initial Clinical Data from Ongoing Phase 1\/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10. Editas Medicine, (available at https:\/\/ir.editasmedicine.com\/news-releases\/news-release-details\/editas-medicine-announces-positive-initial-clinical-data-ongoing)."},{"key":"2023040502200521000_2022.08.24.505004v2.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.12.021"},{"key":"2023040502200521000_2022.08.24.505004v2.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107454"},{"key":"2023040502200521000_2022.08.24.505004v2.10","doi-asserted-by":"publisher","DOI":"10.2174\/1566523054546224"},{"key":"2023040502200521000_2022.08.24.505004v2.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2015.09.008"},{"key":"2023040502200521000_2022.08.24.505004v2.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2015.08.003"},{"key":"2023040502200521000_2022.08.24.505004v2.13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2217\/fvl-2016-0129","article-title":"Designing and building oncolytic viruses","volume":"12","year":"2017","journal-title":"Future Virol"},{"key":"2023040502200521000_2022.08.24.505004v2.14","doi-asserted-by":"publisher","DOI":"10.1126\/science.272.5259.263"},{"key":"2023040502200521000_2022.08.24.505004v2.15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1214441110"},{"key":"2023040502200521000_2022.08.24.505004v2.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03432-4"},{"key":"2023040502200521000_2022.08.24.505004v2.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-022-01436-z"},{"key":"2023040502200521000_2022.08.24.505004v2.18","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1016\/j.cell.2022.11.016","article-title":"Engineered cell entry links receptor biology with single-cell genomics","volume":"185","year":"2022","journal-title":"Cell"},{"key":"2023040502200521000_2022.08.24.505004v2.19","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2016.27"},{"key":"2023040502200521000_2022.08.24.505004v2.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109207"},{"key":"2023040502200521000_2022.08.24.505004v2.21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07845-z"},{"key":"2023040502200521000_2022.08.24.505004v2.22","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa561"},{"key":"2023040502200521000_2022.08.24.505004v2.23","doi-asserted-by":"publisher","DOI":"10.1089\/crispr.2020.0095"},{"key":"2023040502200521000_2022.08.24.505004v2.24","first-page":"914","article-title":"Lentiviral Capsid-Mediated Streptococcus pyogenes Cas9 Ribonucleoprotein Delivery for Efficient and Safe Multiplex Genome Editing","volume":"4","year":"2021","journal-title":"CRISPR J"},{"key":"2023040502200521000_2022.08.24.505004v2.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14957-y"},{"key":"2023040502200521000_2022.08.24.505004v2.26","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.omtn.2018.09.006","article-title":"Transient Retrovirus-Based CRISPR\/Cas9 All-in-One Particles for Efficient, Targeted Gene Knockout","volume":"13","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2023040502200521000_2022.08.24.505004v2.27","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz093"},{"key":"2023040502200521000_2022.08.24.505004v2.28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41551-020-00656-y","article-title":"Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice","volume":"5","year":"2021","journal-title":"Nat Biomed Eng"},{"key":"2023040502200521000_2022.08.24.505004v2.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-00781-8"},{"key":"2023040502200521000_2022.08.24.505004v2.30","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","year":"2020","journal-title":"Nat. Rev. Clin. Oncol"},{"key":"2023040502200521000_2022.08.24.505004v2.31","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/cac2.12330","article-title":"Antibody variable region engineering for improving cancer immunotherapy","volume":"42","year":"2022","journal-title":"Cancer Commun"},{"key":"2023040502200521000_2022.08.24.505004v2.32","doi-asserted-by":"publisher","DOI":"10.3390\/v14030478"},{"key":"2023040502200521000_2022.08.24.505004v2.33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0560-x"},{"key":"2023040502200521000_2022.08.24.505004v2.34","doi-asserted-by":"crossref","first-page":"103593","DOI":"10.1016\/j.isci.2021.103593","article-title":"GS-CA1 and lenacapavir stabilize the HIV-1 core and modulate the core interaction with cellular factors","volume":"25","year":"2022","journal-title":"iScience"},{"key":"2023040502200521000_2022.08.24.505004v2.35","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4047"},{"key":"2023040502200521000_2022.08.24.505004v2.36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-133785"},{"key":"2023040502200521000_2022.08.24.505004v2.37","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3495(00)76824-X"},{"key":"2023040502200521000_2022.08.24.505004v2.38","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41467-023-36496-y","article-title":"Cell surface protein aggregation triggers endocytosis to maintain plasma membrane proteostasis","volume":"14","year":"2023","journal-title":"Nat. Commun"},{"key":"2023040502200521000_2022.08.24.505004v2.39","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/eji.202049064","article-title":"CAR T cells: Building on the CD19 paradigm","volume":"51","year":"2021","journal-title":"Eur. J. Immunol"},{"key":"2023040502200521000_2022.08.24.505004v2.40","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","article-title":"Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing","volume":"21","year":"2022","journal-title":"Mol. Cancer"},{"key":"2023040502200521000_2022.08.24.505004v2.41","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0594"},{"key":"2023040502200521000_2022.08.24.505004v2.42","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","article-title":"In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo","volume":"11","year":"2020","journal-title":"Nat. Commun"},{"key":"2023040502200521000_2022.08.24.505004v2.43","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","year":"2017","journal-title":"Nat. Nanotechnol"},{"key":"2023040502200521000_2022.08.24.505004v2.44","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1186\/s12967-022-03729-5","article-title":"Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products","volume":"20","year":"2022","journal-title":"J. Transl. Med"},{"key":"2023040502200521000_2022.08.24.505004v2.45","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1089\/hum.2017.009","article-title":"Recombinant Adeno-Associated Viral Integration and Genotoxicity: Insights from Animal Models","volume":"28","year":"2017","journal-title":"Hum. Gene Ther"},{"key":"2023040502200521000_2022.08.24.505004v2.46","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-021-00508-1","article-title":"AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia","volume":"11","year":"2021","journal-title":"Blood Cancer J"},{"key":"2023040502200521000_2022.08.24.505004v2.47","doi-asserted-by":"crossref","first-page":"e1671761","DOI":"10.1080\/2162402X.2019.1671761","article-title":"In vivo generated human CAR T cells eradicate tumor cells","volume":"8","year":"2019","journal-title":"Oncoimmunology"},{"key":"2023040502200521000_2022.08.24.505004v2.48","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.omtm.2022.06.004","article-title":"In vivo generation of CAR T cells in the presence of human myeloid cells","volume":"26","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2023040502200521000_2022.08.24.505004v2.49","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809158"},{"key":"2023040502200521000_2022.08.24.505004v2.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtbi.2015.10.016"},{"key":"2023040502200521000_2022.08.24.505004v2.51","first-page":"89","article-title":"Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model","volume":"52","year":"1992","journal-title":"Cancer Res"},{"key":"2023040502200521000_2022.08.24.505004v2.52","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nchembio.2529","article-title":"Human antibody-based chemically induced dimerizers for cell therapeutic applications","volume":"14","year":"2018","journal-title":"Nat. Chem. Biol"},{"key":"2023040502200521000_2022.08.24.505004v2.53","doi-asserted-by":"crossref","unstructured":"Y. D. Muller , D. P. Nguyen , L. M. R. Ferreira , P. Ho , C. Raffin , The CD28-transmembrane domain mediates chimeric antigen receptor heterodimerization with CD28. bioRxiv (2020) (available at https:\/\/www.biorxiv.org\/content\/10.1101\/2020.09.18.296913v1.abstract).","DOI":"10.1101\/2020.09.18.296913"},{"key":"2023040502200521000_2022.08.24.505004v2.54","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3806"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2022.08.24.505004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T03:31:19Z","timestamp":1768447879000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2022.08.24.505004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":54,"URL":"https:\/\/doi.org\/10.1101\/2022.08.24.505004","relation":{},"subject":[],"published":{"date-parts":[[2022,8,24]]},"subtype":"preprint"}}